コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 reduce this measure of myocardial injury in heart failure with preserved ejection fraction.
2 , but less is known about the association in heart failure with preserved ejection fraction.
3 c hypertensive patients and 10 patients with heart failure with preserved ejection fraction.
4 lenge has been proposed as a way to identify heart failure with preserved ejection fraction.
5 ymptoms, or quality of life in patients with heart failure with preserved ejection fraction.
6 d maximal exercise capacity in patients with heart failure with preserved ejection fraction.
7 harmacokinetic and safety profile of KNO3 in heart failure with preserved ejection fraction.
8 c risk factors and frequent comorbidities in heart failure with preserved ejection fraction.
9 ves exercise duration and quality of life in heart failure with preserved ejection fraction.
10 There are few sex-specific outcome data in heart failure with preserved ejection fraction.
11 with increased lung weights, consistent with heart failure with preserved ejection fraction.
12 still no firmly evidence-based treatment for heart failure with preserved ejection fraction.
13 pear to be at higher risk for development of heart failure with preserved ejection fraction.
14 modify response to therapy in patients with heart failure with preserved ejection fraction.
15 in holds promise as a therapeutic target for heart failure with preserved ejection fraction.
16 osis) is an increasingly recognized cause of heart failure with preserved ejection fraction.
17 iac amyloidosis and patients with nonamyloid heart failure with preserved ejection fraction.
18 rdiac structure or function in patients with heart failure with preserved ejection fraction.
19 ar filling pressure is a cardinal feature of heart failure with preserved ejection fraction.
20 patients with elevated PAWP consistent with heart failure with preserved ejection fraction.
21 changes in cardiac structure and function in heart failure with preserved ejection fraction.
23 4 with AL amyloidosis and 16 with nonamyloid heart failure with preserved ejection fraction]; 86% mal
24 comes in the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction) accordin
25 o define secular trends in the prevalence of heart failure with preserved ejection fraction among pat
26 popularity, especially for diagnosing early heart failure with preserved ejection fraction and exerc
27 of valsartan/sacubitril in the treatment of heart failure with preserved ejection fraction and hyper
28 therapy on cardiac structure and function in heart failure with preserved ejection fraction and on th
29 such as the utility of CR for patients with heart failure with preserved ejection fraction and the c
30 e impact of diabetes mellitus on outcomes in heart failure with preserved ejection fraction and wheth
33 diction models specifically for hospitalized heart failure with preserved ejection fraction are lacki
34 Symptoms of breathlessness in patients with heart failure with preserved ejection fraction are multi
35 ransition from hypertensive heart disease to heart failure with preserved ejection fraction are poorl
36 ssociated with impaired exercise capacity in heart failure with preserved ejection fraction are uncle
37 aseline characteristics of participants with heart failure with preserved ejection fraction as it rel
38 In patients with heart failure with preserved ejection fraction, biomarke
39 s been shown to improve exercise capacity in heart failure with preserved ejection fraction, but stud
40 s been shown to improve exercise capacity in heart failure with preserved ejection fraction, but stud
42 substantial number of patients enrolled in a heart failure with preserved ejection fraction clinical
43 tins might improve outcomes in patients with heart failure with preserved ejection fraction defined a
44 estigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction developme
47 ars of age admitted with acute decompensated heart failure with preserved ejection fraction (ejection
48 ity troponin T (hs-TnT) in 298 patients with heart failure with preserved ejection fraction enrolled
50 Given the chronicity of heart failure with preserved ejection fraction, evidence
52 Subjects with heart failure with preserved ejection fraction exhibited
56 ntrolled trial to measure adverse effects of heart failure with preserved ejection fraction (HF-PEF)
58 es in outcomes in patients hospitalized with heart failure with preserved ejection fraction (HFpEF) (
59 haracteristics and outcomes of patients with heart failure with preserved ejection fraction (HFpEF) a
60 ominent features of myocardial remodeling in heart failure with preserved ejection fraction (HFPEF) a
61 is probably underestimated in patients with heart failure with preserved ejection fraction (HFpEF) a
62 if this relationship is consistent for both heart failure with preserved ejection fraction (HFpEF) a
63 nction occur early during the development of heart failure with preserved ejection fraction (HFpEF) a
65 (Vo2) is similarly impaired in patients with heart failure with preserved ejection fraction (HFpEF) a
67 Because of global aging, the prevalence of heart failure with preserved ejection fraction (HFpEF) c
71 rization of myocardial structural changes in heart failure with preserved ejection fraction (HFpEF) h
78 gnificance of pulmonary hypertension (PH) in heart failure with preserved ejection fraction (HFpEF) i
88 capacity or clinical status of patients with heart failure with preserved ejection fraction (HFpEF) i
94 ejection fraction (EF) into distinct groups: heart failure with preserved ejection fraction (HFpEF) o
95 in the evaluation of patients with suspected heart failure with preserved ejection fraction (HFpEF) o
99 ify cardiovascular features of patients with heart failure with preserved ejection fraction (HFpEF) t
100 of risk factors and disease pathogenesis to heart failure with preserved ejection fraction (HFPEF) v
101 omized trial of sildenafil versus placebo in heart failure with preserved ejection fraction (HFpEF) w
102 ad changes occurring during the evolution of heart failure with preserved ejection fraction (HFpEF),
104 arterial function are useful for diagnosing heart failure with preserved ejection fraction (HFPEF),
105 e natriuretic peptide (BNP) in patients with heart failure with preserved ejection fraction (HFPEF),
106 gh left atrial (LA) dysfunction is common in heart failure with preserved ejection fraction (HFpEF),
108 t ventricular (LV) stiffening contributes to heart failure with preserved ejection fraction (HFpEF),
110 out specific modes of death in patients with heart failure with preserved ejection fraction (HFpEF).
111 diastolic dysfunction and other symptoms of heart failure with preserved ejection fraction (HFpEF).
112 abnormalities are prevalent in patients with heart failure with preserved ejection fraction (HFpEF).
113 agnitude of impaired systolic deformation in heart failure with preserved ejection fraction (HFpEF).
114 ing were shown to be specifically altered in heart failure with preserved ejection fraction (HFPEF).
115 gen consumption (Vo2) in older patients with heart failure with preserved ejection fraction (HFPEF).
116 nd left ventricular filling in patients with heart failure with preserved ejection fraction (HFpEF).
117 d trial of spironolactone versus placebo for heart failure with preserved ejection fraction (HFpEF).
118 cular function and thus exercise capacity in heart failure with preserved ejection fraction (HFPEF).
119 pertension in the diagnosis and treatment of heart failure with preserved ejection fraction (HFpEF).
120 ity may contribute to the pathophysiology of heart failure with preserved ejection fraction (HFpEF).
121 ished marker of risk for adverse outcomes in heart failure with preserved ejection fraction (HFpEF).
122 ts with hypertensive heart disease (HHD) and heart failure with preserved ejection fraction (HFpEF).
123 unction (RVD) is a poor prognostic factor in heart failure with preserved ejection fraction (HFpEF).
124 onal capacity is a hallmark of patients with heart failure with preserved ejection fraction (HFpEF).
125 rgement is associated with adverse events in heart failure with preserved ejection fraction (HFpEF).
126 one of the key pathophysiologic features of heart failure with preserved ejection fraction (HFpEF).
127 ted at improving prognosis for patients with heart failure with preserved ejection fraction (HFpEF).
128 There is no effective medical treatment for heart failure with preserved ejection fraction (HFpEF).
129 reserved left ventricular ejection fraction (heart failure with preserved ejection fraction [HFPEF])
130 ension [IPAH]) or post-capillary (as seen in heart failure with preserved ejection fraction [HFpEF]).
131 erved ejection fraction in the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESER
132 istics and outcomes among 4128 patients with heart failure with preserved ejection fraction in the Ir
133 This may contribute to the greater risk of heart failure with preserved ejection fraction in women.
134 The prevalence of heart failure with preserved ejection fraction increased
135 proportion of patients with the diagnosis of heart failure with preserved ejection fraction increased
136 oid excess, which promotes the transition to heart failure with preserved ejection fraction independe
142 after acute decompensation in patients with heart failure with preserved ejection fraction is high,
148 laboratory at baseline in 935 patients with heart failure with preserved ejection fraction (left ven
149 - to 18-month follow-up in 239 patients with heart failure with preserved ejection fraction (left ven
150 though diastolic dysfunction plays a role in heart failure with preserved ejection fraction, little i
153 alities in cardiac structure and function in heart failure with preserved ejection fraction may help
154 Hemodynamic responses to saline infusion in heart failure with preserved ejection fraction (n=11) we
157 ngiotensin receptor blocker on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUN
158 Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUN
159 res, both alone and in combination, identify heart failure with preserved ejection fraction patients
161 of safety and sustained clinical benefit in heart failure with preserved ejection fraction patients
162 In heart failure with preserved ejection fraction, patients
163 e or unique considerations in women, such as heart failure with preserved ejection fraction, peripher
165 In heart failure with preserved ejection fraction, potentia
166 al Status and Exercise Capacity in Diastolic Heart Failure with Preserved Ejection Fraction (RELAX) c
167 The mechanism of functional limitation in heart failure with preserved ejection fraction remains c
168 vs. Fibrosis Quantification by T1 Mapping in Heart Failure With Preserved Ejection Fraction [STIFFMAP
169 nts with HFPEF enrolled in the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-
170 ove Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction) study wa
173 METHODS AND We randomized 12 subjects with heart failure with preserved ejection fraction to oral K
175 of patients with HFpEF in the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial wer
176 ts included in the I-PRESERVE (Irbesartan in Heart Failure With Preserved Ejection Fraction) trial, c
177 upplementation improves exercise capacity in heart failure with preserved ejection fraction via speci
179 d February 2015, 193 patients with confirmed heart failure with preserved ejection fraction were enro
180 ite Delivery to Improve Exercise Capacity in Heart Failure with Preserved Ejection Fraction), which i
181 Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which wa
183 evelopment of PDD and therapeutic trials for heart failure with preserved ejection fraction will be r
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。